modelC01CX09
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | AngiotensinIi | |
| ATC code: | C01CX09 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 20 | mg |
| volume of distribution: | 0.273 | L |
| clearance: | 3.6 | mL/min/kg |
| other parameters in model implementation | ||
Angiotensin II is a peptide hormone that causes vasoconstriction and an increase in blood pressure. It is used as a vasopressor for the treatment of hypotension, particularly in adults with septic or other distributive shock. It is approved for use in certain countries for this indication.
Pharmacokinetics
Pharmacokinetic parameters for angiotensin II are based on published data from clinical use in adult patients with distributive shock.
References
Csajka, C, et al., & Biollaz, J (2002). Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers. Clinical pharmacokinetics 41(2) 137–152. DOI:10.2165/00003088-200241020-00005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11888333
Kim, TH, et al., & Shin, BS (2015). Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans. The AAPS journal 17(5) 1210–1223. DOI:10.1208/s12248-015-9764-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25990964
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)